← Back to Search

Evidence-Based Practices for High-Risk Veteran Care (RIVET Trial)

N/A
Recruiting
Led By Evelyn T Chang, MD MSHS
Research Sponsored by VA Office of Research and Development
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 30-months
Awards & highlights

RIVET Trial Summary

This trial will test different approaches to increase use of evidence-based practices for high-risk Veterans in primary care, provide rapid data feedback to VHA on high-risk patient care, build capacity for the implementation of evidence-based practices, and train future leaders in high-risk Veteran care.

Who is the study for?
The High-Risk Veteran Initiative is for veterans at high risk of hospitalization, including those with complex care needs who are treated within VA sites in VISN 9, 10, and 12. It aims to improve primary care practices to prevent unnecessary hospital stays.Check my eligibility
What is being tested?
The trial tests two evidence-based interventions: EBQI-LC and EBQI-IC. These are designed to enhance VHA Primary Care by providing comprehensive patient-centered care, better medication management strategies, and reducing avoidable hospitalizations.See study design
What are the potential side effects?
Since the interventions involve healthcare practice improvements rather than medications or medical procedures, traditional side effects aren't expected. However, changes in care may lead to different experiences for patients.

RIVET Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~30-months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 30-months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in the proportion of team-assigned primary care patients in the upper 90th percentile of acute hospitalization risk (identified via VA CAN score) who received the Evidence Based Practice (EBP)
Secondary outcome measures
Adherence to chronic medications (diabetes, hypertension, hyperlipidemia, mental health) (VA Pharmacy Data)
Adoption of Evidence Based Practice (EBP)
Comprehensiveness of Care questions from the RIVET Patient Survey- consisting of three items, which was sourced from the SHEP
+14 more

RIVET Trial Design

4Treatment groups
Active Control
Group I: HCMA-EBQI-ICActive Control1 Intervention
Individual (ongoing) consultation (IC), often described as coaching or supervision, is endorsed by implementation experts as an effective implementation strategy for EBP # 2,Phone-Based Health Coaching for Medication Adherence (HCMA).
Group II: HCMA-EBQI-LCActive Control1 Intervention
Learning collaboratives (LC) are widely used in healthcare settings, as an effective implementation strategy. The LC will be used to increase uptake of EBP # 2,Phone-Based Health Coaching for Medication Adherence (HCMA).
Group III: CACP-EBQI-ICActive Control1 Intervention
Individual (ongoing) consultation (IC), often described as coaching or supervision, is endorsed by implementation experts as an effective implementation strategy for EBP #1, Comprehensive Assessment and Care Planning (CACP) for High-Risk Veterans.
Group IV: CACP-EBQI-LCActive Control1 Intervention
Learning collaboratives (LC) are widely used in healthcare settings, as an effective implementation strategy. The LC will be used to increase uptake of EBP #1, Comprehensive Assessment and Care Planning (CACP) for High-Risk Veterans.

Find a Location

Who is running the clinical trial?

Veterans Integrated Service Network 9UNKNOWN
VA Midwest Health Care NetworkFED
1 Previous Clinical Trials
4,000 Total Patients Enrolled
VA Office of Research and DevelopmentLead Sponsor
1,607 Previous Clinical Trials
3,306,019 Total Patients Enrolled
5 Trials studying Multi-morbidity
1,063 Patients Enrolled for Multi-morbidity

Media Library

EBQI-IC Clinical Trial Eligibility Overview. Trial Name: NCT05050643 — N/A
Multi-morbidity Research Study Groups: HCMA-EBQI-IC, HCMA-EBQI-LC, CACP-EBQI-IC, CACP-EBQI-LC
Multi-morbidity Clinical Trial 2023: EBQI-IC Highlights & Side Effects. Trial Name: NCT05050643 — N/A
EBQI-IC 2023 Treatment Timeline for Medical Study. Trial Name: NCT05050643 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Could you provide an estimation of how many people are eligible for entry into this experiment?

"Correct. According to the records on clinicaltrials.gov, recruitment for this medical trial is currently underway, having first been posted on July 23rd 2021 and most recently updated on August 30th 2022. This project seeks 14 volunteers at 1 designated site of research."

Answered by AI

Is it possible to participate in this experimentation presently?

"This medical study, which was initially posted on July 23rd 2021 is currently accepting patients. The trial's details were recently revised on August 30th 2022 according to clinicaltrials.gov."

Answered by AI
~6 spots leftby Sep 2025